Immatics Announces $125 Million Underwritten Offering

Core Viewpoint - Immatics N.V. has announced an underwritten offering of 12,500,000 ordinary shares at a price of $10.00 per share, aiming to raise gross proceeds of $125 million before expenses [1]. Company Overview - Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, a target expressed in over 50 types of cancer. The company boasts a robust clinical pipeline and the broadest PRAME franchise, which includes TCR T-cell therapies and TCR bispecifics [4]. Offering Details - The offering is expected to close on December 8, 2025, subject to customary closing conditions [1]. - Jefferies, Leerink Partners, and Cantor are acting as joint book-running managers for the offering [2]. - A registration statement for the securities has been filed with the U.S. Securities and Exchange Commission and was declared effective on April 3, 2025 [3].